RFP_BPM003308_Donohue___Associates_-_Initial.pdf
PDF 9 MB Posted
- Attached to
- Master Agreement AZ|CTR057398
- Contract number
- CTR057398
- Issued by
- Arizona
About this file
The document appears to be a fragmented procurement file for a pharmaceutical-related contract, potentially involving the Board of Pharmacy Specialties (BPS) and Michael S. Donohue, Pharm.D. The file contains multiple addenda, payment records, and supplementary materials including drug interaction information and psychotropic utilization data. While the complete contract details are not fully clear, the document suggests a state or local government pharmacy-related procurement process.
The file includes references to drug interaction analysis from UpToDate, tracking of psychotropic medication utilization rates for 2019-2020, and comparison of state and national averages. Payment records indicate a maintenance fee transaction for "Geriatric Pharmacy" totaling $112.50. The document contains detailed charts showing monthly psychotropic medication utilization percentages, with comparisons between 2019 and 2020 state and national averages. However, specific contract terms, pricing structures, renewal options, or precise scope of goods and services are not comprehensively detailed in the provided document fragments.
View the file
Other files
Show all 30
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Addendum 1
6/112020 A-1 Michael S Donohue BPS #IND-922931 bps aoard of PhormQO,J Specloltles®
Logged In: Michael S Doi
Payment Successful
Thank you. Your payment is complete and has been assigned the ID: BPS-PMT-201050. Please note this for future reference
The following payments were received/refunded:
Item Date Description
06/12/2020 Credit - Maintenance Fee - Geriatric Pharmacy
2 06/12/2020 Maintenance Fee - Geriatric Pharmacy 2020
We have also sent the payment receipt via email.
Amount
-12.50
125.00
Total: 112.50 https://portalbps.cyzap.neVdzapps/dbzap.bln/apps/assess/webmembers/seoure/manage?webidc:BPS&pToolCode=PMT&pAssessmentlD=&pSave=Ves
Addendum 2
A-2
Addendum 3
A-3
A-3A-3
A-3 A-3A-3
Addendum 4
A-4
A-4
Addendum 5
A-5
Addendum 6
4/5/2021
A-6
Lexicomp® Drug Interactions - UpToDale
Lexicomp® Drug Interactions
Item List
• SEROquel
• Escitalopram
• Levaqufn [DSC]
DSC: Discontinued brand (equivalent product[s] may be available)
NOTE: This tool does not address chemical compatibility related to 1.V. drug preparation or administration.
© 2021 UpToDate, Inc. and/or its affiliates. All Rights Reserved.
CR] Avoid combination [[] Consider therapy modification
4 Results
CC "'] Monitor therapy l-A J No known interaction e·-1 No action needed
: Filter Results by Item v fc'I Escltalopram (QT-prolonging Antidepressants (Moderate Risk))/ Levaqufn [DSC] (QT-prolonging Quinolone
• Antibiotics (Moderate Risk))
!- �__] Escltalopram {QT-prolonging Antidepressants (Moderate Risk)) I SEROquel (QT-prolonging Antipsychotfcs (Moderate
• Risk))
• I [J SEROquel (Antipsychotic Agents)/ Escitalopram (Serotonergic Agents (High Risk))
[§'-] SEROquel (QT-prolonging Antipsychotics (Moderate Risk)) / Levaquin [DSC] (QT-prolonging Quinolone Antibiotics
• (Moderate Risk))
Disclaimer: Readers are advised that decisions regarding drug therapy must be based on the independent Judgment of the clinician, changing information about a drug (eg, as reflected in the literature and manufacturer's most currant product information), and changing medical practices.
https://www.uptodate.com/drug-interactions/?source=responsive_home#di-analyze 1/1
Addendum 7
Addendum 8
AA-8
\-8
Total Psychotropic Utilization
2019 2020 State Avg Nation Avg
Jan 63.1 69.7 57.9 64.7
Feb 62.8 72 57.9 64.7
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
66.5 72.8 57.9 64.7
65.8 76.4 57.9 64.7
78.8 57.9 64.7
78.2 57.9 64.7
80.7 57.9 64.7
74.5 57.9 64.7
74.3 57.9 64.7
70.9 57.9 64.7
76.9 57.9 64.7
72.6 57.9 64.7
I ., . ' • .._,, ,. ..... -- - -····---.-,--. o --• .. .,,., •-••-•n -- - -· -·-. --·. ·---
Total Psychotropic Utilization l 80 : 70 I
,---••••-••--•• --•-•-• ,.,, .. ,, .. .._,__. ,,..__.., ___ ,,-.--•--•-••-.-•••• ........ ,,, •♦ 0 •o•o ... -..-• .--,,•--•·••• ••"'l••U
; 60
I so
40 -·····-····· .. · -· - - ---.. • --· .. - ·-·---· -----·- .... .... _ --
30 -----.. --,·-----------------· --·-·------ "---··- ·-
20 ·-·---- __________ ,.,. ... ,.--.. ···-.. -·-•-"·----···-·-·--· ..... _____ ,_.� ... -- ··-··-- ·
10 ,,,,,,_.,,, ,.,_,. . .,.,. ,,.,,.._,.-,,..,,. """'" ---••�•-"-"• •••••• .. ••••"""""·'"-•••u-.. •• •••"-••· ••• "" - - -• ""
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
-2019 :;c ·,:·c .. ,2020 -StateAvg -NationAvg
Addendum 9
A-9
Addendum 10
A-10
Addendum 11
A-11
AA-11
A-11
Addendum 12
A-12
Addendum 13
A-12A-13
A-13
Michael Donohue, Pharm.D
President
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
| Blank Page |
File details come from the government source that posted it. Updated .